BRPI0212266B8 - anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico - Google Patents

anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico

Info

Publication number
BRPI0212266B8
BRPI0212266B8 BRPI0212266A BRPI0212266B8 BR PI0212266 B8 BRPI0212266 B8 BR PI0212266B8 BR PI0212266 A BRPI0212266 A BR PI0212266A BR PI0212266 B8 BRPI0212266 B8 BR PI0212266B8
Authority
BR
Brazil
Prior art keywords
antibody
ccr4
therapeutic
drug
production
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Shimizu Akiko
Hosaka Emi
Nakamura Kazuyasu
Shitara Kenya
Koike Masamichi
Original Assignee
Kyowa Hakko Kirin Co Ltd
Kyowa Kirin Co Ltd
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd, Kyowa Kirin Co Ltd, Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kirin Co Ltd
Publication of BR0212266A publication Critical patent/BR0212266A/pt
Publication of BRPI0212266B1 publication Critical patent/BRPI0212266B1/pt
Publication of BRPI0212266B8 publication Critical patent/BRPI0212266B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
BR0212266-9 2001-08-31 2002-08-30 anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico BRPI0212266B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-265144 2001-08-31
JP2001265144 2001-08-31
PCT/JP2002/008828 WO2003018635A1 (fr) 2001-08-31 2002-08-30 Anticorps greffes cdr humains et fragments de ces anticorps

Publications (3)

Publication Number Publication Date
BR0212266A BR0212266A (pt) 2004-10-19
BRPI0212266B1 BRPI0212266B1 (pt) 2020-05-05
BRPI0212266B8 true BRPI0212266B8 (pt) 2021-05-25

Family

ID=19091652

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212266-9 BRPI0212266B8 (pt) 2001-08-31 2002-08-30 anticorpos humanizados anti-ccr4, método de produção dos mesmos, medicamento, e agentes terapêuticos e de diagnóstico

Country Status (22)

Country Link
US (8) US7504104B2 (enExample)
EP (1) EP1449850B9 (enExample)
JP (1) JP4052515B2 (enExample)
KR (1) KR100959248B1 (enExample)
CN (1) CN100430420C (enExample)
AT (1) ATE490277T1 (enExample)
AU (1) AU2002338015B8 (enExample)
BE (1) BE2019C006I2 (enExample)
BR (1) BRPI0212266B8 (enExample)
CA (1) CA2458627C (enExample)
CO (1) CO5560582A2 (enExample)
CY (2) CY1111193T1 (enExample)
DE (1) DE60238503D1 (enExample)
DK (1) DK1449850T3 (enExample)
ES (1) ES2356190T3 (enExample)
FR (1) FR19C1028I2 (enExample)
LU (1) LUC00116I2 (enExample)
MX (1) MXPA04001894A (enExample)
NL (1) NL300985I2 (enExample)
NO (1) NO334858B1 (enExample)
PT (1) PT1449850E (enExample)
WO (1) WO2003018635A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275540B1 (en) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
SI1270595T1 (sl) 2000-03-03 2008-12-31 Kyowa Hakko Kogyo Kk Protitelo proti CCR4 in njegov fragment
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1491209A4 (en) * 2002-02-28 2006-05-17 Kyowa Hakko Kogyo Kk MEANS FOR DIAGNOSIS AND TREATMENT OF INTERSTITIAL PNEUMONIA
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
CN100522998C (zh) 2003-10-01 2009-08-05 协和发酵麒麟株式会社 抗体的稳定化方法和被稳定的溶液状抗体制剂
AU2004279739A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Composition of antibody capable of specifically binding CCR4
DE602004029934D1 (de) 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
WO2007013627A1 (ja) * 2005-07-28 2007-02-01 Kyowa Hakko Kogyo Co., Ltd. Bリンパ腫およびホジキンリンパ腫の治療剤
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
EP2476438B1 (en) 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
CN102863533B (zh) * 2010-06-21 2013-12-11 中国科学技术大学 抗体人源化改造方法
US20140072983A1 (en) 2010-08-10 2014-03-13 Amgen Inc. Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
JP6310845B2 (ja) * 2012-07-06 2018-04-11 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連脊髄症患者の治療方法および治療剤
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
WO2015179236A1 (en) 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
US20180271861A1 (en) 2015-07-14 2018-09-27 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
CN116731186B (zh) * 2023-07-07 2023-12-26 武汉爱博泰克生物科技有限公司 抗人IgG-Fc兔单克隆抗体及其制备方法、多核苷酸分子、表达载体和宿主细胞
WO2025212536A1 (en) * 2024-04-01 2025-10-09 Moonlight Bio, Inc. Therapeutic antibody epitope-tagged car t cells for enhanced control and safety
CN119775429B (zh) * 2024-12-26 2026-08-07 南开大学 一种抗人her2/ccr4的双特异性抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
BR9814957A (pt) 1997-11-12 2000-10-03 Hoffmann La Roche Tratamento de doenças imune mediadas por célula auxiliar "t" tipo 2 com antagonistas retinóides
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
CA2332128A1 (en) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hypercalcemic crisis
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1050307A1 (en) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
SI1270595T1 (sl) * 2000-03-03 2008-12-31 Kyowa Hakko Kogyo Kk Protitelo proti CCR4 in njegov fragment
DE602004029934D1 (de) * 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament

Also Published As

Publication number Publication date
NL300985I2 (en) 2019-11-21
CA2458627A1 (en) 2003-03-06
DK1449850T3 (da) 2011-02-14
NO20040976L (no) 2004-06-01
AU2002338015B2 (en) 2008-02-07
BRPI0212266B1 (pt) 2020-05-05
US10131711B2 (en) 2018-11-20
HK1073851A1 (zh) 2005-10-21
US20090227012A1 (en) 2009-09-10
ES2356190T3 (es) 2011-04-05
EP1449850A1 (en) 2004-08-25
FR19C1028I1 (enExample) 2019-05-17
DE60238503D1 (de) 2011-01-13
US20150315285A1 (en) 2015-11-05
KR100959248B1 (ko) 2010-05-26
JP4052515B2 (ja) 2008-02-27
NL300985I1 (en) 2019-05-08
WO2003018635A1 (fr) 2003-03-06
CO5560582A2 (es) 2005-09-30
NO334858B1 (no) 2014-06-23
EP1449850B9 (en) 2011-05-11
CN100430420C (zh) 2008-11-05
BE2019C006I2 (enExample) 2021-11-22
AU2002338015B8 (en) 2008-03-20
JPWO2003018635A1 (ja) 2004-12-09
LUC00116I2 (enExample) 2019-12-27
US20110059524A1 (en) 2011-03-10
EP1449850A4 (en) 2005-08-10
LUC00116I1 (enExample) 2019-05-02
US7504104B2 (en) 2009-03-17
US8900584B2 (en) 2014-12-02
US20130273038A1 (en) 2013-10-17
US20180030146A1 (en) 2018-02-01
EP1449850B1 (en) 2010-12-01
ATE490277T1 (de) 2010-12-15
US20120177643A1 (en) 2012-07-12
PT1449850E (pt) 2011-02-02
CN1575303A (zh) 2005-02-02
US10590203B2 (en) 2020-03-17
US20030175273A1 (en) 2003-09-18
CY1111193T1 (el) 2015-06-11
CA2458627C (en) 2013-09-10
FR19C1028I2 (fr) 2021-02-19
US7842797B2 (en) 2010-11-30
BR0212266A (pt) 2004-10-19
US8143058B2 (en) 2012-03-27
US20140186349A1 (en) 2014-07-03
CY2019022I2 (el) 2019-11-27
KR20040044492A (ko) 2004-05-28
CY2019022I1 (el) 2019-11-27
MXPA04001894A (es) 2005-09-08
US9051371B2 (en) 2015-06-09

Similar Documents

Publication Publication Date Title
BR0212266A (pt) Anticorpo enxertado com cdr humano e fragmento de anticorpo do mesmo
Kovarik et al. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation
Hanna et al. A phase II study of methylphenidate for the treatment of fatigue
Garcia-Manero et al. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes
Caimi et al. The antiCD19 antibody drug immunoconjugate loncastuximab achieves responses in DLBCL relapsing after antiCD19 CAR-T cell therapy
Salt et al. Comparison of the pharmacokinetic properties of triamcinolone and dexamethasone for local therapy of the inner ear
BRPI0511755A (pt) composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
BR112022003811A2 (pt) Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução
CY1105942T1 (el) Sgk3 ως διαγνωστικος και θepαπευτικος στοχος
BR112021021350A2 (pt) Entrega intracelular de anticorpos anti kras formulados em nanocápsulas
Maus et al. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents
Dahm et al. Evaluation of levels of triamcinolone acetonide in human perilymph and plasma after intratympanic application in patients receiving cochlear implants: A randomized clinical trial
Cavaletti et al. Neuro-and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients.
Chandra et al. Test‐dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non‐malignant disorders
Kerdel et al. Mast cell participation during the elicitation of murine allergic contact hypersensitivity
UY24063A1 (es) Empleo de concentrados con contenido de factor von willebrand (vwf) como terapia de combinacion en la terapia con antitromboticos y fibrinoliticos
Hoffstedt et al. Penetration of ceftazidime into extracellular fluid in patients
Miettinen et al. Blood flow-independent accumulation of cisplatin in the guinea pig cochlea
Eke et al. Disposition kinetics of ceftriaxone and determination of its therapeutic dose in dogs
WO2022165275A8 (en) Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
Trinquand et al. Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study
IL183924A (en) Use of a combination of active agents in the preparation of pharmaceutical compositions
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
Huber Clinical experience with a new norgestimate-containing oral contraceptive.
Gracitelli et al. Uso do voriconazol na ceratite recorrente causada por fungo Paecilomyces lilacinus

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: KYOWA HAKKO KIRIN CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: KYOWA KIRIN CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: KYOWA KIRIN CO., LTD. (JP)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/05/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 30/08/2022